How did McKesson's revenue and expenses trend in Q3 2025?

McKesson's revenue and certain expenses exhibited notable growth and strategic adjustments in Q3 2025, which are key takeaways from their financial performance during the quarter:

1. Revenue Growth: McKesson's revenue increased by 18% year-over-year, reaching $95.3 billion in Q3 2025, up from $80.9 billion in the corresponding quarter of the previous year. This growth was primarily driven by:
   • A 19% increase in the U.S. Pharmaceutical segment, with revenues reaching $87.1 billion.
   • A 14% rise in the Prescription Technology Solutions segment, resulting in revenues of $1.4 billion.
   • A 45% surge in GLP-1 medications, contributing to the overall revenue growth.
2. Operating Profit Expansion: The company's adjusted operating profit grew by 16% to $1.5 billion, up from $1.29 billion in Q3 2024. This was supported by enhanced operational efficiencies and cost controls.
3. Gross Profit Increase: Gross profit rose by 7% to $3.3 billion, up from $3.09 billion in the prior year's same quarter.
4. Operating Expenses: Operating expenses increased by 2% to $1.9 billion, primarily due to higher costs supporting growth in the U.S. Pharmaceutical segment.
5. International Segment Performance: The International segment saw a 6% revenue increase, reaching $3.9 billion, attributed to higher pharmaceutical distribution volumes in the Canadian business.
6. Strategic Investments and Acquisitions: McKesson made a significant move to acquire an 80% controlling interest in PRISM Vision for approximately $850 million, enhancing its specialty services platform and capabilities in ophthalmology and retina management. This acquisition is expected to contribute to the company's growth, with projections of adding $0.20 to $0.30 to adjusted EPS within the first year and $0.65 to $0.75 by the end of the third year.

In summary, McKesson's Q3 2025 financial performance showcased strong revenue growth, particularly in its Pharmaceutical and Prescription Technology Solutions segments, alongside strategic investments that are poised to enhance long-term value.